1
|
Joly J, Hudik E, Lecart S, Roos D, Verkuijlen P, Wrona D, Siler U, Reichenbach J, Nüsse O, Dupré-Crochet S. Membrane Dynamics and Organization of the Phagocyte NADPH Oxidase in PLB-985 Cells. Front Cell Dev Biol 2020; 8:608600. [PMID: 33365312 PMCID: PMC7751761 DOI: 10.3389/fcell.2020.608600] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2020] [Accepted: 10/20/2020] [Indexed: 11/13/2022] Open
Abstract
Neutrophils are the first cells recruited at the site of infections, where they phagocytose the pathogens. Inside the phagosome, pathogens are killed by proteolytic enzymes that are delivered to the phagosome following granule fusion, and by reactive oxygen species (ROS) produced by the NADPH oxidase. The NADPH oxidase complex comprises membrane proteins (NOX2 and p22phox), cytoplasmic subunits (p67phox, p47phox, and p40phox) and the small GTPase Rac. These subunits assemble at the phagosomal membrane upon phagocytosis. In resting neutrophils the catalytic subunit NOX2 is mainly present at the plasma membrane and in the specific granules. We show here that NOX2 is also present in early and recycling endosomes in human neutrophils and in the neutrophil-like cell line PLB-985 expressing GFP-NOX2. In the latter cells, an increase in NOX2 at the phagosomal membrane was detected by live-imaging after phagosome closure, probably due to fusion of endosomes with the phagosome. Using super-resolution microscopy in PLB-985 WT cells, we observed that NOX2 forms discrete clusters in the plasma membrane. The number of clusters increased during frustrated phagocytosis. In PLB-985NCF1ΔGT cells that lack p47phox and do not assemble a functional NADPH oxidase, the number of clusters remained stable during phagocytosis. Our data suggest a role for p47phox and possibly ROS production in NOX2 recruitment at the phagosome.
Collapse
Affiliation(s)
- Jérémy Joly
- Université Paris-Saclay, CNRS U8000, Institut de Chimie Physique, Orsay, France
| | - Elodie Hudik
- Université Paris-Saclay, CNRS U8000, Institut de Chimie Physique, Orsay, France
| | - Sandrine Lecart
- Light Microscopy Core Facility, Imagerie-Gif, Institut de Biologie Intégrative de la Cellule (I2BC), CEA, CNRS, Université Paris-Saclay, Gif-sur-Yvette, France
| | - Dirk Roos
- Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands
| | - Paul Verkuijlen
- Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands
| | - Dominik Wrona
- Division of Gene and Cell Therapy, Institute for Regenerative Medecine, University of Zurich, Zurich, Switzerland
| | - Ulrich Siler
- Division of Gene and Cell Therapy, Institute for Regenerative Medecine, University of Zurich, Zurich, Switzerland
| | - Janine Reichenbach
- Division of Gene and Cell Therapy, Institute for Regenerative Medecine, University of Zurich, Zurich, Switzerland
| | - Oliver Nüsse
- Université Paris-Saclay, CNRS U8000, Institut de Chimie Physique, Orsay, France
| | | |
Collapse
|
2
|
Matlung HL, Babes L, Zhao XW, van Houdt M, Treffers LW, van Rees DJ, Franke K, Schornagel K, Verkuijlen P, Janssen H, Halonen P, Lieftink C, Beijersbergen RL, Leusen JHW, Boelens JJ, Kuhnle I, van der Werff Ten Bosch J, Seeger K, Rutella S, Pagliara D, Matozaki T, Suzuki E, Menke-van der Houven van Oordt CW, van Bruggen R, Roos D, van Lier RAW, Kuijpers TW, Kubes P, van den Berg TK. Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis. Cell Rep 2019; 23:3946-3959.e6. [PMID: 29949776 DOI: 10.1016/j.celrep.2018.05.082] [Citation(s) in RCA: 209] [Impact Index Per Article: 41.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2017] [Revised: 03/30/2018] [Accepted: 05/23/2018] [Indexed: 02/07/2023] Open
Abstract
Destruction of cancer cells by therapeutic antibodies occurs, at least in part, through antibody-dependent cellular cytotoxicity (ADCC), and this can be mediated by various Fc-receptor-expressing immune cells, including neutrophils. However, the mechanism(s) by which neutrophils kill antibody-opsonized cancer cells has not been established. Here, we demonstrate that neutrophils can exert a mode of destruction of cancer cells, which involves antibody-mediated trogocytosis by neutrophils. Intimately associated with this is an active mechanical disruption of the cancer cell plasma membrane, leading to a lytic (i.e., necrotic) type of cancer cell death. Furthermore, this mode of destruction of antibody-opsonized cancer cells by neutrophils is potentiated by CD47-SIRPα checkpoint blockade. Collectively, these findings show that neutrophil ADCC toward cancer cells occurs by a mechanism of cytotoxicity called trogoptosis, which can be further improved by targeting CD47-SIRPα interactions.
Collapse
Affiliation(s)
- Hanke L Matlung
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - Liane Babes
- Immunology Research Group, University of Calgary, Calgary, Alberta, Canada
| | - Xi Wen Zhao
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - Michel van Houdt
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - Louise W Treffers
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - Dieke J van Rees
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - Katka Franke
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - Karin Schornagel
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - Paul Verkuijlen
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - Hans Janssen
- Division of Cell Biology, the Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - Pasi Halonen
- Division of Molecular Carcinogenesis and the NKI Robotics and Screening Center, the Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - Cor Lieftink
- Division of Molecular Carcinogenesis and the NKI Robotics and Screening Center, the Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - Roderick L Beijersbergen
- Division of Molecular Carcinogenesis and the NKI Robotics and Screening Center, the Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - Jeanette H W Leusen
- Immunotherapy Laboratory, Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Jaap J Boelens
- U-DANCE, Laboratory for Translational Immunology, UMC Utrecht, Utrecht, the Netherlands; Department of Pediatrics, Blood and Marrow Transplantation Program, UMC Utrecht, Utrecht, the Netherlands
| | - Ingrid Kuhnle
- Department of Pediatrics, University Medicine Göttingen, Göttingen, Germany
| | | | - Karl Seeger
- Department of Pediatric Oncology/Hematology, Otto-Heubner-Center for Pediatric and Adolescent Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Sergio Rutella
- Division of Translational Medicine, Sidra Medical and Research Center, Doha, Qatar
| | - Daria Pagliara
- Department of Pediatric Hematology/Oncology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy
| | - Takashi Matozaki
- Department of Biochemistry and Molecular Biology, Division of Molecular and Cellular Signaling, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
| | - Eiji Suzuki
- Department of Breast Surgery, Kyoto University Hospital, Kyoto, Japan
| | | | - Robin van Bruggen
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - Dirk Roos
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - Rene A W van Lier
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - Taco W Kuijpers
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Emma Children's Hospital, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands
| | - Paul Kubes
- Immunology Research Group, University of Calgary, Calgary, Alberta, Canada
| | - Timo K van den Berg
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Department of Molecular Cell Biology and Immunology, VU Medical Center, Amsterdam, the Netherlands.
| |
Collapse
|
3
|
Treffers LW, Zhao XW, van der Heijden J, Nagelkerke SQ, van Rees DJ, Gonzalez P, Geissler J, Verkuijlen P, van Houdt M, de Boer M, Kuijpers TW, van den Berg TK, Matlung HL. Genetic variation of human neutrophil Fcγ receptors and SIRPα in antibody-dependent cellular cytotoxicity towards cancer cells. Eur J Immunol 2017; 48:344-354. [DOI: 10.1002/eji.201747215] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2017] [Revised: 08/25/2017] [Accepted: 09/18/2017] [Indexed: 01/28/2023]
Affiliation(s)
- Louise W. Treffers
- Sanquin Research, and Landsteiner Laboratory; Academic Medical Center; University of Amsterdam; Amsterdam The Netherlands
| | - Xi Wen Zhao
- Sanquin Research, and Landsteiner Laboratory; Academic Medical Center; University of Amsterdam; Amsterdam The Netherlands
| | - Joris van der Heijden
- Sanquin Research, and Landsteiner Laboratory; Academic Medical Center; University of Amsterdam; Amsterdam The Netherlands
| | - Sietse Q. Nagelkerke
- Sanquin Research, and Landsteiner Laboratory; Academic Medical Center; University of Amsterdam; Amsterdam The Netherlands
| | - Dieke J. van Rees
- Sanquin Research, and Landsteiner Laboratory; Academic Medical Center; University of Amsterdam; Amsterdam The Netherlands
| | - Patricia Gonzalez
- Sanquin Research, and Landsteiner Laboratory; Academic Medical Center; University of Amsterdam; Amsterdam The Netherlands
| | - Judy Geissler
- Sanquin Research, and Landsteiner Laboratory; Academic Medical Center; University of Amsterdam; Amsterdam The Netherlands
| | - Paul Verkuijlen
- Sanquin Research, and Landsteiner Laboratory; Academic Medical Center; University of Amsterdam; Amsterdam The Netherlands
| | - Michel van Houdt
- Sanquin Research, and Landsteiner Laboratory; Academic Medical Center; University of Amsterdam; Amsterdam The Netherlands
| | - Martin de Boer
- Sanquin Research, and Landsteiner Laboratory; Academic Medical Center; University of Amsterdam; Amsterdam The Netherlands
| | - Taco W. Kuijpers
- Sanquin Research, and Landsteiner Laboratory; Academic Medical Center; University of Amsterdam; Amsterdam The Netherlands
- Emma Children's Hospital; Academic Medical Centre; University of Amsterdam; Amsterdam The Netherlands
| | - Timo K. van den Berg
- Sanquin Research, and Landsteiner Laboratory; Academic Medical Center; University of Amsterdam; Amsterdam The Netherlands
- Department of Molecular Cell Biology and Immunology; VU medical center; Amsterdam The Netherlands
| | - Hanke L. Matlung
- Sanquin Research, and Landsteiner Laboratory; Academic Medical Center; University of Amsterdam; Amsterdam The Netherlands
| |
Collapse
|
4
|
Gazendam RP, van de Geer A, van Hamme JL, Tool ATJ, van Rees DJ, Aarts CEM, van den Biggelaar M, van Alphen F, Verkuijlen P, Meijer AB, Janssen H, Roos D, van den Berg TK, Kuijpers TW. Impaired killing of Candida albicans by granulocytes mobilized for transfusion purposes: a role for granule components. Haematologica 2016; 101:587-96. [PMID: 26802050 DOI: 10.3324/haematol.2015.136630] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2015] [Accepted: 01/14/2016] [Indexed: 12/21/2022] Open
Abstract
Granulocyte transfusions are used to treat neutropenic patients with life-threatening bacterial or fungal infections that do not respond to anti-microbial drugs. Donor neutrophils that have been mobilized with granulocyte-colony stimulating factor (G-CSF) and dexamethasone are functional in terms of antibacterial activity, but less is known about their fungal killing capacity. We investigated the neutrophil-mediated cytotoxic response against C. albicans and A. fumigatus in detail. Whereas G-CSF/dexamethasone-mobilized neutrophils appeared less mature as compared to neutrophils from untreated controls, these cells exhibited normal ROS production by the NADPH oxidase system and an unaltered granule mobilization capacity upon stimulation. G-CSF/dexamethasone-mobilized neutrophils efficiently inhibited A. fumigatus germination and killed Aspergillus and Candida hyphae, but the killing of C. albicans yeasts was distinctly impaired. Following normal Candida phagocytosis, analysis by mass spectrometry of purified phagosomes after fusion with granules demonstrated that major constituents of the antimicrobial granule components, including major basic protein (MBP), were reduced. Purified MBP showed candidacidal activity, and neutrophil-like Crisp-Cas9 NB4-KO-MBP differentiated into phagocytes were impaired in Candida killing. Together, these findings indicate that G-CSF/dexamethasone-mobilized neutrophils for transfusion purposes have a selectively impaired capacity to kill Candida yeasts, as a consequence of an altered neutrophil granular content.
Collapse
Affiliation(s)
- Roel P Gazendam
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, The Netherlands
| | - Annemarie van de Geer
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, The Netherlands
| | - John L van Hamme
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, The Netherlands
| | - Anton T J Tool
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, The Netherlands
| | - Dieke J van Rees
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, The Netherlands
| | - Cathelijn E M Aarts
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, The Netherlands
| | - Maartje van den Biggelaar
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, The Netherlands
| | - Floris van Alphen
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, The Netherlands
| | - Paul Verkuijlen
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, The Netherlands
| | - Alexander B Meijer
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, The Netherlands
| | - Hans Janssen
- The Netherlands Netherlands Cancer Institute, Division of Cell Biology, Amsterdam, The Netherlands
| | - Dirk Roos
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, The Netherlands
| | - Timo K van den Berg
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, The Netherlands
| | - Taco W Kuijpers
- Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, The Netherlands Emma Children's Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| |
Collapse
|
5
|
Szilagyi K, Gazendam RP, van Hamme JL, Tool ATJ, van Houdt M, Vos WAJW, Verkuijlen P, Janssen H, Belot A, Juillard L, Förster-Waldl E, Boztug K, Kraal G, de Winther MPJ, Kuijpers TW, van den Berg TK. Impaired microbial killing by neutrophils from patients with protein kinase C delta deficiency. J Allergy Clin Immunol 2015; 136:1404-7.e1-10. [PMID: 26233929 DOI: 10.1016/j.jaci.2015.06.016] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2015] [Accepted: 06/03/2015] [Indexed: 01/12/2023]
Affiliation(s)
- Katka Szilagyi
- Department of Blood Cell Research, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
| | - Roel P Gazendam
- Department of Blood Cell Research, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
| | - John L van Hamme
- Department of Blood Cell Research, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Anton T J Tool
- Department of Blood Cell Research, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Michel van Houdt
- Department of Blood Cell Research, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Wilhelm A J W Vos
- Department of Blood Cell Research, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Paul Verkuijlen
- Department of Blood Cell Research, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Hans Janssen
- Division of Cell Biology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Alexandre Belot
- Hôpital Femme Mère Enfant, Hospices Civils de Lyon and Université de Lyon, Lyon, France
| | - Laurent Juillard
- CarMen U1060 Université de Lyon, Lyon, France; Service de Néphrologie, H. E. Herriot Hospices Civils de Lyon, Lyon, France
| | - Elisabeth Förster-Waldl
- Divison of Neonatology, Paediatric Intensive Care & Neuropaediatrics, Department of Paediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
| | - Kaan Boztug
- Divison of Neonatology, Paediatric Intensive Care & Neuropaediatrics, Department of Paediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
| | - Georg Kraal
- Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
| | - Menno P J de Winther
- Department of Medical Biochemistry, Experimental Vascular Biology, Academic Medical Center, Amsterdam, The Netherlands
| | - Taco W Kuijpers
- Department of Blood Cell Research, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Pediatric Hematology, Immunology and Infectious Disease, Emma Children's Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Timo K van den Berg
- Department of Blood Cell Research, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| |
Collapse
|
6
|
Szilagyi K, Meijer AB, Neele AE, Verkuijlen P, Leitges M, Dabernat S, Förster-Waldl E, Boztug K, Belot A, Kuijpers TW, Kraal G, de Winther MPJ, van den Berg TK. PKCδ is dispensible for oxLDL uptake and foam cell formation by human and murine macrophages. Cardiovasc Res 2014; 104:467-76. [DOI: 10.1093/cvr/cvu213] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
|
7
|
Orelio C, van der Sluis RM, Verkuijlen P, Nethe M, Hordijk PL, van den Berg TK, Kuijpers TW. Altered intracellular localization and mobility of SBDS protein upon mutation in Shwachman-Diamond syndrome. PLoS One 2011; 6:e20727. [PMID: 21695142 PMCID: PMC3113850 DOI: 10.1371/journal.pone.0020727] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2010] [Accepted: 05/09/2011] [Indexed: 11/18/2022] Open
Abstract
Shwachman-Diamond Syndrome (SDS) is a rare inherited disease caused by mutations in the SBDS gene. Hematopoietic defects, exocrine pancreas dysfunction and short stature are the most prominent clinical features. To gain understanding of the molecular properties of the ubiquitously expressed SBDS protein, we examined its intracellular localization and mobility by live cell imaging techniques. We observed that SBDS full-length protein was localized in both the nucleus and cytoplasm, whereas patient-related truncated SBDS protein isoforms localize predominantly to the nucleus. Also the nucleo-cytoplasmic trafficking of these patient-related SBDS proteins was disturbed. Further studies with a series of SBDS mutant proteins revealed that three distinct motifs determine the intracellular mobility of SBDS protein. A sumoylation motif in the C-terminal domain, that is lacking in patient SBDS proteins, was found to play a pivotal role in intracellular motility. Our structure-function analyses provide new insight into localization and motility of the SBDS protein, and show that patient-related mutant proteins are altered in their molecular properties, which may contribute to the clinical features observed in SDS patients.
Collapse
Affiliation(s)
- Claudia Orelio
- Sanquin Research and Landsteiner Laboratory of the Academic Medical Center (AMC), Department of Blood Cell Research, University of Amsterdam, Amsterdam, The Netherlands
| | - Renée M. van der Sluis
- Sanquin Research and Landsteiner Laboratory of the Academic Medical Center (AMC), Department of Blood Cell Research, University of Amsterdam, Amsterdam, The Netherlands
| | - Paul Verkuijlen
- Sanquin Research and Landsteiner Laboratory of the Academic Medical Center (AMC), Department of Blood Cell Research, University of Amsterdam, Amsterdam, The Netherlands
| | - Micha Nethe
- Sanquin Research and Landsteiner Laboratory of the Academic Medical Center (AMC), Department of Molecular Cell Biology, University of Amsterdam, Amsterdam, The Netherlands
| | - Peter L. Hordijk
- Sanquin Research and Landsteiner Laboratory of the Academic Medical Center (AMC), Department of Molecular Cell Biology, University of Amsterdam, Amsterdam, The Netherlands
| | - Timo K. van den Berg
- Sanquin Research and Landsteiner Laboratory of the Academic Medical Center (AMC), Department of Blood Cell Research, University of Amsterdam, Amsterdam, The Netherlands
| | - Taco W. Kuijpers
- Sanquin Research and Landsteiner Laboratory of the Academic Medical Center (AMC), Department of Blood Cell Research, University of Amsterdam, Amsterdam, The Netherlands
- Emma Children's Hospital, Academic Medical Center (AMC), Amsterdam, The Netherlands
- * E-mail:
| |
Collapse
|
8
|
Emile Gras JC, Verkuijlen P, Frants RR, Havekes LM, van Berkel TJC, Biessen EAL, van Dijk KW. Specific and efficient targeting of adenovirus vectors to macrophages: application of a fusion protein between an adenovirus-binding fragment and avidin, linked to a biotinylated oligonucleotide. J Gene Med 2006; 8:668-78. [PMID: 16532513 DOI: 10.1002/jgm.895] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND The application of serotype 5 adenoviruses (Ad5) in macrophages is hampered by the absence of the endogenous coxsackie adenovirus receptor (CAR). METHODS To overcome this limitation, we first generated a linker protein consisting of the virus-binding domain of CAR and the C-terminus of avidin. Second, to target macrophages, this linker protein was equipped with the biotinylated (bio) oligonucleotide dA6G10, which was previously shown to display a high affinity for the scavenger receptor A (SR-A). RESULTS As compared to nontargeted virus, the linker protein equipped with bio-dA6G10 showed a 500-fold increased reporter gene expression in mouse macrophage RAW264.7 cells. A linker protein equipped with a bio-dA16 control oligonucleotide was inactive. Moreover, the bio-dA6G10-equipped linker showed a 390-fold increased luciferase expression in the macrophage cell line J774 and 276- and 150-fold increased reporter gene expression in primary peritoneal and bone marrow (BM)-derived macrophages, respectively. Using BM-derived macrophages from SR-A knockout mice, it was shown that the dA6G10-mediated uptake is predominantly SR-A-mediated. CONCLUSIONS Thus, we have developed a novel tool to link biotinylated ligands to a virus-binding fragment of CAR and have exploited this linker protein to extend the applicability of Ad5 to infect transformed and primary macrophages.
Collapse
Affiliation(s)
- J C Emile Gras
- Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | | | | | | | | | | | | |
Collapse
|
9
|
Hendriks YMC, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger F, Sandkuijl L, Møller P, Genuardi M, Van Houwelingen H, Tops C, Van Puijenbroek M, Verkuijlen P, Kenter G, Van Mil A, Meijers-Heijboer H, Tan GB, Breuning MH, Fodde R, Wijnen JT, Bröcker-Vriends AHJT, Vasen H. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004; 127:17-25. [PMID: 15236168 DOI: 10.1053/j.gastro.2004.03.068] [Citation(s) in RCA: 282] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
BACKGROUND & AIMS Hereditary nonpolyposis colorectal carcinoma (HNPCC) is caused by a mutated mismatch repair (MMR) gene. The aim of our study was to determine the cumulative risk of developing cancer in a large series of MSH6 mutation carriers. METHODS Mutation analysis was performed in 20 families with a germline mutation in MSH6. We compared the cancer risks between MSH6 and MLH1/MSH2 mutation carriers. Microsatellite instability (MSI) analysis and immunohistochemistry (IHC) were performed in the available tumors. RESULTS A total of 146 MSH6 mutation carriers were identified. In these carriers, the cumulative risk for colorectal carcinoma was 69% for men, 30% for women, and 71% for endometrial carcinoma at 70 years of age. The risk for all HNPCC-related tumors was significantly lower in MSH6 than in MLH1 or MSH2 mutation carriers (P = 0.002). In female MSH6 mutation carriers, the risk for colorectal cancer was significantly lower (P = 0.0049) and the risk for endometrial cancer significantly higher (P = 0.02) than in MLH1 and MSH2 mutation carriers. In male carriers, the risk for colorectal cancer was lower in MSH6 mutation carriers, but the difference was not significant (P = 0.0854). MSI analysis in colorectal tumors had a sensitivity of 86% in predicting a MMR defect. IHC in all tumors had a sensitivity of 90% in predicting a mutation in MSH6. CONCLUSIONS We recommend starting colonoscopic surveillance in female MSH6 mutation carriers from age 30 years. Prophylactic hysterectomy might be considered in carriers older than 50 years. MSI and IHC analysis are sensitive tools to identify families eligible for MSH6 mutation analysis.
Collapse
Affiliation(s)
- Yvonne M C Hendriks
- Center of Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Meijers-Heijboer H, Wijnen J, Vasen H, Wasielewski M, Wagner A, Hollestelle A, Elstrodt F, van den Bos R, de Snoo A, Tjon A Fat G, Brekelmans C, Jagmohan S, Franken P, Verkuijlen P, van den Ouweland A, Chapman P, Tops C, Möslein G, Burn J, Lynch H, Klijn J, Fodde R, Schutte M. The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 2003; 72:1308-14. [PMID: 12690581 PMCID: PMC1180284 DOI: 10.1086/375121] [Citation(s) in RCA: 157] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2002] [Accepted: 02/24/2003] [Indexed: 11/04/2022] Open
Abstract
Because of genetic heterogeneity, the identification of breast cancer-susceptibility genes has proven to be exceedingly difficult. Here, we define a new subset of families with breast cancer characterized by the presence of colorectal cancer cases. The 1100delC variant of the cell cycle checkpoint kinase CHEK2 gene was present in 18% of 55 families with hereditary breast and colorectal cancer (HBCC) as compared with 4% of 380 families with non-HBCC (P<.001), thus providing genetic evidence for the HBCC phenotype. The CHEK2 1100delC mutation was, however, not the major predisposing factor for the HBCC phenotype but appeared to act in synergy with another, as-yet-unknown susceptibility gene(s). The unequivocal definition of the HBCC phenotype opens new avenues to search for this putative HBCC-susceptibility gene.
Collapse
Affiliation(s)
- Hanne Meijers-Heijboer
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - Juul Wijnen
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - Hans Vasen
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - Marijke Wasielewski
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - Anja Wagner
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - Antoinette Hollestelle
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - Fons Elstrodt
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - Renate van den Bos
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - Anja de Snoo
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - Grace Tjon A Fat
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - Cecile Brekelmans
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - Shantie Jagmohan
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - Patrick Franken
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - Paul Verkuijlen
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - Ans van den Ouweland
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - Pamela Chapman
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - Carli Tops
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - Gabriela Möslein
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - John Burn
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - Henry Lynch
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - Jan Klijn
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - Riccardo Fodde
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| | - Mieke Schutte
- Departments of Clinical Genetics and Medical Oncology, Erasmus MC, Rotterdam; Center for Human and Clinical Genetics and Department of Gastroentrology, Leiden University Medical Center, Leiden, The Netherlands; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; Department of Surgery, Heinrich Heine University, Düsseldorf; and Department of Preventive Medicine and Public Health, Creighton University, Omaha
| |
Collapse
|
11
|
Wagner A, Barrows A, Wijnen JT, van der Klift H, Franken PF, Verkuijlen P, Nakagawa H, Geugien M, Jaghmohan-Changur S, Breukel C, Meijers-Heijboer H, Morreau H, van Puijenbroek M, Burn J, Coronel S, Kinarski Y, Okimoto R, Watson P, Lynch JF, de la Chapelle A, Lynch HT, Fodde R. Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. Am J Hum Genet 2003; 72:1088-100. [PMID: 12658575 PMCID: PMC1180263 DOI: 10.1086/373963] [Citation(s) in RCA: 160] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2002] [Accepted: 12/30/2002] [Indexed: 12/14/2022] Open
Abstract
The identification of germline mutations in families with HNPCC is hampered by genetic heterogeneity and clinical variability. In previous studies, MSH2 and MLH1 mutations were found in approximately two-thirds of the Amsterdam-criteria-positive families and in much lower percentages of the Amsterdam-criteria-negative families. Therefore, a considerable proportion of HNPCC seems not to be accounted for by the major mismatch repair (MMR) genes. Does the latter result from a lack of sensitivity of mutation detection techniques, or do additional genes underlie the remaining cases? In this study we address these questions by thoroughly investigating a cohort of clinically selected North American families with HNPCC. We analyzed 59 clinically well-defined U.S. families with HNPCC for MSH2, MLH1, and MSH6 mutations. To maximize mutation detection, different techniques were employed, including denaturing gradient gel electrophoresis, Southern analysis, microsatellite instability, immunohistochemistry, and monoallelic expression analysis. In 45 (92%) of the 49 Amsterdam-criteria-positive families and in 7 (70%) of the 10 Amsterdam-criteria-negative families, a mutation was detected in one of the three analyzed MMR genes. Forty-nine mutations were in MSH2 or MLH1, and only three were in MSH6. A considerable proportion (27%) of the mutations were genomic rearrangements (12 in MSH2 and 2 in MLH1). Notably, a deletion encompassing exons 1-6 of MSH2 was detected in seven apparently unrelated families (12% of the total cohort) and was subsequently proven to be a founder. Screening of a second U.S. cohort with HNPCC from Ohio allowed the identification of two additional kindreds with the identical founder deletion. In the present study, we show that optimal mutation detection in HNPCC is achieved by combining accurate and expert clinical selection with an extensive mutation detection strategy. Notably, we identified a common North American deletion in MSH2, accounting for approximately 10% of our cohort. Genealogical, molecular, and haplotype studies showed that this deletion represents a North American founder mutation that could be traced back to the 19th century.
Collapse
Affiliation(s)
- Anja Wagner
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | - Alicia Barrows
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | - Juul Th. Wijnen
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | - Heleen van der Klift
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | - Patrick F. Franken
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | - Paul Verkuijlen
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | - Hidewaki Nakagawa
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | - Marjan Geugien
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | - Shantie Jaghmohan-Changur
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | - Cor Breukel
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | - Hanne Meijers-Heijboer
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | - Hans Morreau
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | - Marjo van Puijenbroek
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | - John Burn
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | - Stephany Coronel
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | - Yulia Kinarski
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | - Ross Okimoto
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | - Patrice Watson
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | - Jane F. Lynch
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | - Albert de la Chapelle
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | - Henry T. Lynch
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | - Riccardo Fodde
- Center for Human and Clinical Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; and Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
| |
Collapse
|
12
|
Hutter P, Wijnen J, Rey-Berthod C, Thiffault I, Verkuijlen P, Farber D, Hamel N, Bapat B, Thibodeau SN, Burn J, Wu J, MacNamara E, Heinimann K, Chong G, Foulkes WD. An MLH1 haplotype is over-represented on chromosomes carrying an HNPCC predisposing mutation in MLH1. J Med Genet 2002; 39:323-7. [PMID: 12011148 PMCID: PMC1735107 DOI: 10.1136/jmg.39.5.323] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND The mismatch repair gene, MLH1, appears to occur as two main haplotypes at least in white populations. These are referred to as A and G types with reference to the A/G polymorphism at IVS14-19. On the basis of preliminary experimental data, we hypothesised that deviations from the expected frequency of these two haplotypes could exist in carriers of disease associated MLH1 germline mutations. METHODS We assembled a series (n=119) of germline MLH1 mutation carriers in whom phase between the haplotype and the mutation had been conclusively established. Controls, without cancer, were obtained from each contributing centre. Cases and controls were genotyped for the polymorphism in IVS14. RESULTS Overall, 66 of 119 MLH1 mutations occurred on a G haplotype (55.5%), compared with 315 G haplotypes on 804 control chromosomes (39.2%, p=0.001). The odds ratio (OR) of a mutation occurring on a G rather than an A haplotype was 1.93 (95% CI 1.29 to 2.91). When we compared the haplotype frequencies in mutation bearing chromosomes carried by people of different nationalities with those seen in pooled controls, all groups showed a ratio of A/G haplotypes that was skewed towards G, except the Dutch group. On further analysis of the type of each mutation, it was notable that, compared with control frequencies, deletion and substitution mutations were preferentially represented on the G haplotype (p=0.003 and 0.005, respectively). CONCLUSION We have found that disease associated mutations in MLH1 appear to occur more often on one of only two known ancient haplotypes. The underlying reason for this observation is obscure, but it is tempting to suggest a possible role of either distant regulatory sequences or of chromatin structure influencing access to DNA sequence. Alternatively, differential behaviour of otherwise similar haplotypes should be considered as prime areas for further study.
Collapse
Affiliation(s)
- P Hutter
- Unit of Genetics, Institut Central des Hôpitaux Valaisans, Sion, Switzerland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|